Home » Stocks » Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc. (BCLI)

Stock Price: $13.27 USD -0.12 (-0.90%)
Updated Aug 14, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 418.38M
Revenue (ttm) n/a
Net Income (ttm) -28.83M
Shares Out 31.53M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $13.27
Previous Close $13.39
Change ($) -0.12
Change (%) -0.90%
Day's Open 13.46
Day's Range 13.00 - 13.62
Day's Volume 359,084
52-Week Range 3.50 - 17.20

More Stats

Market Cap 418.38M
Enterprise Value 403.97M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 31.53M
Float 27.31M
EPS (basic) -1.16
EPS (diluted) -1.15
FCF / Share -0.96
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.42M
Short Ratio 4.38
Short % of Float 12.12%
Beta 1.18
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 41.79
Revenue n/a
Operating Income -28.92M
Net Income -28.83M
Free Cash Flow -28.10M
Net Cash 14.41M
Net Cash / Share 0.46
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -128.73%
ROE -1,086.85%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(29.39% upside)
Current: $13.27
Target: 17.17
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-23.00-14.06-5.00-5.08-8.54-7.42-5.04-3.52-3.89-2.59
Net Income-23.25-13.95-4.95-4.98-8.49-9.25-4.90-3.43-3.92-2.42
Shares Outstanding21.9120.0018.7818.6618.4113.6610.749.178.015.94
Earnings Per Share-1.06-0.70-0.26-0.27-0.46-0.68-0.46-0.30-0.45-0.45
Operating Cash Flow-11.25-12.39-2.36-5.86-7.41-4.49-4.05-2.94-2.22-2.07
Capital Expenditures-0.47-0.37-0.18-0.10-0.05-0.16-0.11-0.09-0.05-0.01
Free Cash Flow-11.72-12.76-2.54-5.96-7.45-4.65-4.16-3.03-2.27-2.07
Cash & Equivalents0.577.067.769.9915.968.543.504.091.920.09
Total Debt2.37--------0.14
Net Cash / Debt-1.807.067.769.9915.968.543.504.091.92-0.04
Book Value-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Brainstorm Cell Therapeutics Inc.
Country United States
Employees 37
CEO Chaim Lebovits

Stock Information

Ticker Symbol BCLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCLI


Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.